Progyny, Inc.
NASDAQ:PGNYMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $2.66B
- Beta
- 1.04
- P/E (TTM)
- 31.4
- EPS (TTM)
- $0.84
Volume 0.88M
Average 1.49M
PGNY Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Progyny, Inc.NASDAQ: PGNY
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin dips below year-ago levels
Q2 FY2026 selling, general & admin of $49.3M fell 9.7% year over year, behind the +4.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.
Context
- Selling, general & admin amounted to 17.0% of revenue in FY2025, up 1.1 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $229.6M (+4.7%) for the fiscal year ending Dec 2026, a slowdown from the +17.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $49.3M+3.4% QoQ
- Last fiscal yearDec 2025
- $219.21M+17.9% YoY
- LTMJun 2026
- $209.96M+4.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 219.21M USD
- Year-over-year change
- +17.9%
- 4-year CAGR
- +28.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 219.21M | +17.9% |
| FY2024 | 2024-12-31 | 185.91M | +5.3% |
| FY2023 | 2023-12-31 | 176.62M | +22.7% |
| FY2022 | 2022-12-31 | 143.98M | +80.4% |
| FY2021 | 2021-12-31 | 79.8M | — |
Selling, General & Admin vs competitors
How PGNY compares with its peers on the latest reported figures
- PGNY's LTM Jun 2026 selling, general & admin of $209.96M is the 2nd highest of the 3 companies compared; the peer median is $228.4M.
- Its year-over-year change of +4.6% is the 2nd highest of 3, against a peer median of +31.5%.
- Selling, general & admin amounts to 16.0% of revenue for PGNY, versus a peer median of 32.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $342.77M | +64.1% | +25.9% | 25.2% | |
| LTM Jun 2026 | $209.96M | +4.6% | +15.0% | 16.0% | |
| LTM Mar 2026 | $114.04M | -1.0% | +16.9% | 40.3% | |
| Peer median (excluding PGNY) | $228.4M | +31.5% | +21.4% | 32.7% | |
Competitors are the stored peer set for PGNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 500.62M | 786.91M | 1.09B | 1.17B | 1.29B |
| Cost of Revenue | 388.49M | 619.59M | 849.8M | 913.86M | 984.18M |
| Gross Profit | 112.14M | 167.33M | 238.8M | 253.36M | 304.48M |
| Gross Margin | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 79.8M | 143.98M | 176.62M | 185.91M | 219.21M |
| Operating Expenses | 79.8M | 143.98M | 176.62M | 185.91M | 219.21M |
| Depreciation & Amortization | 1.3M | 1.6M | 2.28M | 3.18M | 4.95M |
| EBITDA | 33.74M | 26.04M | 72.97M | 86.38M | 100.38M |
| EBITDA Margin | 6.7% | 3.3% | 6.7% | 7.4% | 7.8% |
| Operating Income | 32.34M | 23.34M | 62.18M | 67.46M | 85.28M |
| Operating Margin | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% |
| Interest Income | 461K | 814K | 8.51M | 15.75M | 10.16M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 95K | 1.1M | 8.51M | 15.75M | 10.16M |
| Income Before Tax | 32.44M | 24.44M | 70.69M | 83.2M | 95.43M |
| Pre-Tax Margin | 6.5% | 3.1% | 6.5% | 7.1% | 7.4% |
| Income Tax Expense | (33.33M) | (5.92M) | 8.65M | 28.87M | 36.91M |
| Net Income | 65.77M | 30.36M | 62.04M | 54.34M | 58.52M |
| Net Margin | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% |
| EPS (Basic) | 0.74 | 0.33 | 0.65 | 0.59 | 0.68 |
| EPS (Diluted) | 0.66 | 0.30 | 0.62 | 0.57 | 0.65 |
| Weighted Avg Shares | 89.11M | 92.2M | 95.02M | 91.48M | 85.23M |
| Weighted Avg Shares (Diluted) | 100.36M | 99.96M | 100.67M | 95.45M | 89.46M |
Progyny, Inc.
NASDAQ:PGNY
Intrinsic Alpha fair value
Locked
Current Price
$36.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.